47756 Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices 

Place: The Westin Arlington Gateway, 801 

N. Glebe Road, Arlington, VA 22203. 

Contact Person: Jimok Kim, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–9223, Jimok.kim@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Stroke Clinical Trials. 

Date: November 2, 2017. 

Time: 8:30 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Palomar, 2121 P Street NW., 

Washington, DC 20037. 

Contact Person: Shanta Rajaram, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–6033, rajarams@mail.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; R13 Review. 

Date: November 8, 2017. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Ernie Lyons, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–4056, lyonse@ninds.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Jointly Sponsored T32 

Review. 

Date: December 7–8, 2017. 

Time: 8:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites by Hilton 

Alexandria Old Town, 1900 Diagonal Road, 

Alexandria, VA 22314. 

Contact Person: Jimok Kim, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, NINDS/NIH/DHHS, Neuroscience 

Center, 6001 Executive Blvd., Suite 3204, 

MSC 9529, Bethesda, MD 20892–9529, (301) 

496–9223, Jimok.kim@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: October 6, 2017. 

Sylvia L. Neal, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–22142 Filed 10–12–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Submission for OMB Review; 30-Day 

Comment Request; Specimen 

Resource Locator (NCI) 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act of 1995, the 

National Institutes of Health (NIH) has 

submitted to the Office of Management 

and Budget (OMB) a request for review 

and approval of the information 

collection listed below. 

DATES: Comments regarding this 

information collection are best assured 

of having their full effect if received 

within 30 days of October 13, 2017. 

ADDRESSES: Written comments and/or 

suggestions regarding the item(s) 

contained in this notice, especially 

regarding the estimated public burden 

and associated response time, should be 

directed to the: Office of Management 

and Budget, Office of Regulatory Affairs, 

OIRA_submission@omb.eop.gov or by 

fax to (202) 395–6974, Attention: Desk 

Officer for NIH. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact: Joanne Demchok, 

Program Director, Cancer Diagnosis 

Program, Division of Cancer Treatment 

and Diagnosis, 9609 Medical Center 

Drive, Rockville, MD 20892 or call nontoll-free number (240) 276–5959 or 

Email your request, including your 

address to: peterjo@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: This 

proposed information collection was 

previously published in the Federal 

Register on July 28, 2017 and allowed 

60 days for public comment. No public 

comments were received. The purpose 

of this notice is to allow an additional 

30 days for public comment. The 

National Cancer Institute (NCI), 

National Institutes of Health, may not 

conduct or sponsor, and the respondent 

is not required to respond to, an 

information collection that has been 

extended, revised, or implemented on or 

after October 1, 1995, unless it displays 

a currently valid OMB control number. 

In compliance with Section 

3507(a)(1)(D) of the Paperwork 

Reduction Act of 1995, the National 

Institutes of Health (NIH) has submitted 

to the Office of Management and Budget 

(OMB) a request for review and 

approval of the information collection 

listed below. 

Proposed Collection: Specimen 

Resource Locator, 0925–0703 

Reinstatement without Change, National 

Cancer Institute (NCI), National 

Institutes of Health (NIH). 

Need and Use of Information 

Collection: The availability of 

specimens and associated data is critical 

to increase our knowledge of cancer 

biology, and to translate important 

research discoveries to clinical 

application. The discovery and 

validation of cancer prevention markers 

require access, by researchers, to quality 

clinical biospecimens. In response, to 

this need, the National Cancer 

Institute’s (NCI) Cancer Diagnosis 

Program has developed, and is 

expanding, a searchable database: 

Specimen Resource Locator (SRL). The 

SRL allows scientists in the research 

community and the NCI to locate 

specimens needed for their research. 

The SRL will list all NCI supported 

repositories and their links. This 

administrative submission is an on-line 

form that will collect information to 

manage and improve a program and its 

resources for the use of all scientists. 

This submission does not involve any 

analysis. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

105. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden hours 

Private Sector .............................................................. Initial Request ........ 70 1 30/60 35 

State Government ....................................................... 70 1 30/60 35 

Federal Government .................................................... 60 1 30/60 30 

Private Sector .............................................................. Annual Update ....... 20 1 5/60 2 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
Federal Register / Vol. 82, No. 197 / Friday, October 13, 2017 / Notices 47757 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total 

burden hours 

State Government ....................................................... 20 1 5/60 2 

Federal Government .................................................... 10 1 5/60 1 

Total ...................................................................... 250 250 ........................ 105 

Dated: October 6, 2017. 

Karla Bailey, 

Project Clearance Liaison, National Cancer 

Institute, National Institutes of Health. 

[FR Doc. 2017–22156 Filed 10–12–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

NHLBI Special Emphasis Panel. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

NHLBI Single Site CLTR Review. 

Date: November 6, 2017. 

Time: 8:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Chang Sook Kim, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7188, Bethesda, MD 20892–7924, 301–827– 

7940, carolko@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: October 6, 2017. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–22141 Filed 10–12–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive Patent 

License: Devices and Systems For 

Treating Valvular Regurgitation 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Heart, Lung and 

Blood Institute (NHLBI), National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an Exclusive 

Patent License to Cook Medical 

Technologies, LLC, located in 

Bloomington, Indiana, to practice the 

inventions embodied in the patent 

applications listed in the 

Supplementary Information section of 

this notice. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NHLBI Office of 

Technology Transfer and Development 

October 30, 2017 will be considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

exclusive patent license should be 

directed to: Michael Shmilovich, Esq., 

Senior Licensing and Patent Manager, 

31 Center Drive Room 4A29, MSC2479, 

Bethesda, MD 20892–2479, phone 

number 301–435–5019, or shmilovm@

mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

following and all continuing U.S. and 

foreign patents/patent applications 

thereof are the intellectual properties to 

be licensed under the prospective 

agreement to Cook Medical 

Technologies, LLC: NIH Ref. No. E–027– 

2013/0 ‘‘Devices And Methods for 

Treating Functional Triscupid Valve 

Regurgitation’’ U.S. Provisional Patent 

Application 61/785,652 filed March 14, 

2013, International Patent Application 

PCT/US2014/025300 filed under the 

Patent Cooperation Treaty on March 13, 

2014, European Patent Application 

14723540.2 having an international 

filing date of March 13, 2014, and U.S. 

Patent Application 14/776,488 also 

having an international filing date of 

March 13, 2014. NIH Ref. No. E–115– 

2013/0 ‘‘Encircling Suture Delivery 

System For Flexible Circumferential 

Suture,’’ U.S. Provisional Patent 

Application 61/834,357 filed June 12, 

2013, International Patent Application 

PCT/US2014/040716 filed under the 

Patent Cooperation Treaty on June 3, 

2014, European Patent Application 

14735030.0 having an international 

filing date of June 3, 2014 and U.S. 

Patent Application 14/898,020 also 

having an international filing date of 

June 3, 2014. The patent rights in these 

inventions have been assigned to the 

Government of the United States of 

America. The prospective exclusive 

patent License territory may be 

worldwide and a field of use limited to 

valvular regurgitation. 

The invention embodied in NIH Ref. 

No. E–027–2013/0 relates to devices and 

methods for treating functional 

tricuspid valve regurgitation and related 

conditions. The devices are adapted for 

applying force to an area of a patient’s 

heart along or near the atrioventricular 

groove and can include a tensioning 

element configured to be delivered by a 

flexible member guided through a 

catheter and positioned generally along 

or near the atrioventricular groove, and 

a compression member that can be 

positioned along the tensioning element 

and over a desired segment of the 

atrioventricular groove to develop force 

to be applied to an adjacent area of the 

heart by selective tensioning of the 

tensioning element. 

The invention embodied in NIH Ref 

No. E–115–2013/0 relates to devices for 

delivering encircling implants that can 

include two separate limbs held 

together at a distal articulation by the 

implant being delivered. The implant 

can comprise a suture and/or a braided 


asabaliauskas on DSKBBXCHB2PROD with NOTICES